Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7

7 May 2019

Abstract excerpt

Abstract Recent studies suggest that targeting transcriptional machinery can lead to potent and selective anticancer effects in cancers dependent on high and constant expression of certain transcription factors for growth and survival. Cyclin-dependent kinase 7 (CDK7) is the catalytic subunit of the CDK-activating kinase complex. Its function is required for both cell-cycle regulation and transcriptional control...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31064851
DOI: 10.1158/0008-5472.can-19-0119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7PMID 31064851Read ↗

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?Semantic proximity Read ↗

CDK7 inhibitors as anticancer drugsSemantic proximity Read ↗

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSemantic proximity Read ↗

CDK9 inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathwaySemantic proximity Read ↗

CDK7 in breast cancer: mechanisms of action and therapeutic potentialSemantic proximity Read ↗

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting CDK7 to overcome hypomethylating agent resistance in acute myeloid leukemiaSemantic proximity Read ↗

Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in NeuroblastomaSemantic proximity Read ↗

Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitorSemantic proximity Read ↗

Mechanistic Roles of Transcriptional Cyclin-Dependent Kinases in Oncogenesis: Implications for Cancer TherapySemantic proximity Read ↗

Cdk5 in Oncology: Recent Advances and Future ProspectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.